secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001193125-25-310611
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Mirum Pharmaceuticals to Acquire Bluejay Therapeutics for Up to $820M
---------------------------------------------------------------------

- Mirum pays $250M cash and up to 5.2M shares (≈$370M) at closing, plus up to $200M in milestone payments for Bluejay Therapeutics.
- Acquisition adds brelovitug, a Phase 3 monoclonal antibody for chronic hepatitis D (HDV) with Breakthrough Therapy and PRIME designations.
- Mirum also raised $200M in a PIPE from investors including Morgan Stanley, Leerink, Cantor, Raymond James, and Citizens JMP.
- Top-line Phase 3 data for brelovitug expected in second half of 2026; BLA submission anticipated in first half of 2027.
- Transaction expected to close in Q1 2026, subject to HSR clearance, stockholder approval, and other customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000119312525310611/0001193125-25-310611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000119312525310611/d46722d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-310611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer